Orexo calls for early redemption of its outstanding senior secured social bonds 2024/2028
Uppsala, Sweden – March 4, 2026 – On December 31, 2025, Orexo AB (publ) (“Orexo” or the “Company”) (STO:ORX) (OTCQX:ORXOY) announced, that Orexo’s divestment of the rights to Zubsolv® (buprenorphine/naloxone) sublingual tablet CIII, for the treatment of opioid use disorder, in the US to Dexcel Pharma USA had been completed. It was also announced that the net proceeds from the transaction will be used to, amongst other things, redeem the Company’s outstanding senior secured social bonds 2024/2028 (ISIN: SE0021515277) with a total outstanding nominal amount of SEK 500,000,000 (the “Bonds”).
Consequently, the Company today announces that it has exercised its right to make an early redemption of the Bonds in accordance with the terms and conditions of the Bonds. The Bonds will be redeemed at a price of 103.25 percent of the nominal amount plus accrued and unpaid interest up to and including the settlement date for the early redemption, which will be March 30, 2026 (the “Redemption Price”), in accordance with the terms and conditions of the Bonds. The Redemption Price will be paid to each person who is registered as owner of Bonds in the debt register maintained by Euroclear Sweden at the close of business on March 23, 2026. An unconditional notice of the early redemption is sent to directly registered owners of the Bonds in the debt register as of March 3, 2026.
In connection with the early redemption, the Bonds will be delisted from the sustainable bonds list of Nasdaq Stockholm.
The information was sent for publication, through the agency of the contact persons set out below, on March 4, 2026, at 8.00 CET.
For further information contact:
Nikolaj Sørensen, President and CEO
Fredrik Järrsten, EVP and CFO
Lena Wange, IR & Communications Director
Tel: +46 18 780 88 00, +1 855 982 7658
E-mail: ir@orexo.com
About Orexo
Orexo is a Swedish pharmaceutical company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to route of administration, manufacturing, and distribution of drugs. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm’s main market and trades as ADRs on the OTCQX market in the United States.
For more information, please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.